hotspot -WSS

hotspot

author：fashion 2025-09-29 23:28:00 - browse：91168

LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.

Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： FDA approves updated Covid vaccines

WSS

Diverse clinical trials: Why aren’t we there yet?

Neuroscience startup Neumora files for IPO

Radiation, mainstay of cancer treatment, begins a fade

How to make Best Hospitals ratings actually useful for patients

How to make Best Hospitals ratings actually useful for patients

White House touts steps to stem shortages of cancer treatments

explore

hotspot

leisure time

The cancer drug shortage isn’t new — and neither are the solutions

FDA proposes changes to key medical devices approval pathway

The high cost of giving birth even with insurance

Study finds new variant for Parkinson’s in African populations

How to save PrEP access — and even expand it

How to make AI work for medicine

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

AstraZeneca bets AAV gene therapy will still deliver the goods

Guidelines to prevent youth baseball injuries need more muscle

As pharma fights Medicare drug negotiation, hospitals, docs silent

focus

Generate Biomedicines machine learning biotech raises $273M

Feds fine Medicare Advantage plans for overcharging members

Generate Biomedicines machine learning biotech raises $273M

PEPFAR is under serious threat — and so is global health

Apellis safety probe of eye disease drug centers on injection needle

AstraZeneca bets AAV gene therapy will still deliver the goods

leisure time

explore

hotspot

hotspot